Safety and Efficacy Study of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Chronic Rhinosinusitis (CRS) With or Without Nasal Polyps
Category & Conditions: Neurological Diseases and Conditions
Medicine: Nurtec® ODT (Rimegepant)
ClinicalTrials.gov Identifier (NCT): NCT05248997
Protocol ID: C4951015 (BHV3000-316)
Open Plain Language Summary Result:
Click here